Climacteric最新文献_第8页

Good night and good luck. 晚安，祝你好运。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2287312

Rod Baber

引用次数: 0

Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis. MHT在女性心血管疾病患者中的应用：一项系统综述和荟萃分析。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2273524

S Bontempo, L Yeganeh, R Giri, A J Vincent

{"title":"Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis.","authors":"S Bontempo, L Yeganeh, R Giri, A J Vincent","doi":"10.1080/13697137.2023.2273524","DOIUrl":"10.1080/13697137.2023.2273524","url":null,"abstract":"This systematic review assesses the effect of menopausal hormone therapy (MHT) on cardiovascular outcomes and risk factors in postmenopausal women with cardiovascular disease (CVD). The Medline, Embase and Cochrane databases were searched from inception to December 2022 for randomized controlled trials (RCTs) and observational studies using methodology from a previous Cochrane review. Quality assessment used the Cochrane risk of bias tool and Newcastle-Ottawa scale, respectively. From 5647 studies identified, 29 (23 RCTs and six observational studies) were included. Most studies were conducted in North America or Europe and investigated oral estrogens. Participants were older with varying frequency of cardiac risk factors and underlying CVD. No significant difference was observed between MHT users and controls regarding primary outcomes of non-fatal myocardial infarction, cardiovascular death or stroke. No difference in frequency of angina, heart failure and transient ischemic attacks was observed. Inconsistent effects of MHT on angiographic progression were seen and varied with glycemic status. Estradiol had a positive effect on flow-mediated dilatation. Limited studies identified differing effects of MHT on cardiac risk factors, varying with estrogen preparation. This study confirms no benefit of MHT for secondary CVD prevention, highlighting evidence limitations and the importance of shared decision-making when managing menopausal symptoms in women with CVD.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"93-103"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71478661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reproductive milestones across the lifespan and cardiovascular disease risk in women. 妇女一生中的生殖里程碑和心血管疾病风险。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2259793

C A Stuenkel

{"title":"Reproductive milestones across the lifespan and cardiovascular disease risk in women.","authors":"C A Stuenkel","doi":"10.1080/13697137.2023.2259793","DOIUrl":"10.1080/13697137.2023.2259793","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of death for women across the developed and developing world. Beyond traditional cardiovascular risk factors, a number of reproductive milestones have been recognized. The goal of this White Paper, issued by the International Menopause Society in conjunction with World Menopause Day 2023, is to highlight female reproductive milestones in terms of potential cardiovascular risk and to review recommendations for minimizing that risk. The primary milestones discussed relate to menstrual cyclicity, adverse pregnancy outcomes, breast cancer treatments and menopause. Each of these categories has a number of permutations that have been shown in observational studies to be associated with increased cardiovascular risks. In current clinical care, recognition of these reproductive milestones has been encouraged so patients can be informed and motivated to engage in primary prevention of CVD early in their life course rather than retrospectively later in life. Options for specifically targeted care with specialist teams are designed to enhance success with risk identification, screening and possible detection of CVD and, optimally, primary or secondary prevention of CVD. Promoting cardiovascular health of women has far-reaching effects for themselves, their families and their progeny. It is time to make women's cardiovascular health a priority.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"5-15"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41116255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular disease in women: take it to heart. 女性的心血管疾病：放在心上。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2286140

Cynthia A Stuenkel

引用次数: 0

Good night and good luck. 晚安，祝你好运。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2287312

Rod Baber

引用次数: 0

Testosterone and the heart: friend or foe? 睾酮与心脏：是敌是友？

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2023-09-04 DOI: 10.1080/13697137.2023.2250252

S R Davis

引用次数: 0

Closing the gap: cardiovascular disease in women. 缩小差距：女性心血管疾病。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2281935

M Nathani, B Vogel, R Mehran

引用次数: 0

Pregnancy-associated risk factors for future cardiovascular disease - early prevention strategies warranted. 与妊娠有关的未来心血管疾病风险因素--应采取早期预防策略。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2287628

T S Mikkola, O Ylikorkala

{"title":"Pregnancy-associated risk factors for future cardiovascular disease - early prevention strategies warranted.","authors":"T S Mikkola, O Ylikorkala","doi":"10.1080/13697137.2023.2287628","DOIUrl":"10.1080/13697137.2023.2287628","url":null,"abstract":"We summarize convincing evidence that future cardiovascular disease (CVD) risk increases one-fold to four-fold for women with a history of pregnancy complicated by hypertensive disorders, gestational diabetes, fetal growth restriction, placental abruption and preterm birth. A concomitant occurrence of two or more complications in the same pregnancy further potentiates the risk. These women should be informed of their future CVD risks during the postpartum check-up taking place after delivery, and also, if needed, treated, for example, for persisting high blood pressure. In these women with high blood pressure, check-up should take place within 7-10 days, and if severe hypertension, within 72 h. Women without diagnostic signs and symptoms should be examined for the first time 1-2 years postpartum and then at intervals of 2-3 years for a complete CVD risk profile including clinical and laboratory assessments. Women should be informed for future CVD risks and their effective prevention with healthy lifestyle factors. Combined oral contraceptives should be avoided or used with caution. If laboratory or other clinical findings indicate, then vigorous treatments consisting of non-medical and medical (antihypertensives, statins, antidiabetic and anti-obesity therapies) interventions should be initiated early with liberal indications and with ambitious therapeutic goals. Low-dose aspirin and menopausal hormone therapy should be used in selected cases. Active control and treatment policies of these women with pregnancy-related risks will likely result in decreases of CVD occurrence in later life.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"41-46"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Women's cardiovascular health - the cardio-oncologic jigsaw. 女性心血管健康--心血管肿瘤拼图。

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2286382

M Ray, L E Butel-Simoes, J M Lombard, I I C Nordman, A Van der Westhuizen, N J Collins, D T M Ngo, A L Sverdlov

{"title":"Women's cardiovascular health - the cardio-oncologic jigsaw.","authors":"M Ray, L E Butel-Simoes, J M Lombard, I I C Nordman, A Van der Westhuizen, N J Collins, D T M Ngo, A L Sverdlov","doi":"10.1080/13697137.2023.2286382","DOIUrl":"10.1080/13697137.2023.2286382","url":null,"abstract":"Improvements in cancer care have led to an exponential increase in cancer survival. This is particularly the case for breast cancer, where 5-year survival in Australia exceeds 90%. Cardiovascular disease (CVD) has emerged as one of the competing causes of morbidity and mortality among cancer survivors, both as a complication of cancer therapies and because the risk factors for cancer are shared with those for CVD. In this review we cover the key aspects of cardiovascular care for women throughout their cancer journey: the need for baseline cardiovascular risk assessment and management, a crucial component of the cardiovascular care; the importance of long-term surveillance for ongoing maintenance of cardiovascular health; and strong evidence for the beneficial effects of physical exercise to improve both cancer and cardiovascular outcomes. There is general disparity in cardiovascular outcomes for women, which is further exacerbated when both CVD and cancer co-exist. Collaboration between oncology and cardiac services, with an emergence of the whole field of cardio-oncology, allows for expedited investigation and treatment for these patients. This collaboration as well as a holistic approach to patient care and key role of patients' general practitioners are essential to ensure long-term health of people living with, during and beyond cancer.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"60-67"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138799374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular risk assessment in women: which women are suited for menopausal hormone therapy? 女性心血管风险评估：哪些女性适合更年期激素治疗？

IF 2.8 4区医学

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI: 10.1080/13697137.2023.2259799

A H E M Maas

{"title":"Cardiovascular risk assessment in women: which women are suited for menopausal hormone therapy?","authors":"A H E M Maas","doi":"10.1080/13697137.2023.2259799","DOIUrl":"10.1080/13697137.2023.2259799","url":null,"abstract":"Individual risk assessment for atherosclerotic cardiovascular disease is important for safe menopausal hormone prescription. Besides the traditional risk factors, female-specific risk variables related to pregnancy and gynecologic conditions importantly contribute to a more tailored risk assessment in women at middle age. Of these, prior pre-eclampsia/HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome and early spontaneous menopause (<40 years) seem to be the strongest adverse risk variables. Concomitant inflammatory disorders should also be taken into account. Adding a coronary artery calcium score with a computed tomography scan to risk assessment has a high predictive value for future cardiovascular events. This should be considered to discriminate between low-risk and high-risk women when uncertainty exists. In women at intermediate risk, menopausal hormone therapy can be easily combined with preventive medication if cardiovascular risk factors are present. In women at higher risk who have severe disabling vasomotor symptoms, a lower dosage of hormone therapy can be considered in good collaboration between the gynecologist and the cardiologist/vascular specialist.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"89-92"},"PeriodicalIF":2.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71478660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0